Table 2

Results of multivariate analysis on predictors for progression of clinical joint damage in patients with PsA

VariableRelative rate of joint damage progression (95% CI)p Value
Duration of disease at first visit (group 2 vs group 1)1.38 (1.08 to 1.77)0.01
Age (1 year increase)1.03 (1.02 to 10.4)<0.0001
Sex (men vs women)1.02 (0.81 to 1.29)0.84
Education status at first visit (college or university vs less than high school)0.82 (0.64 to 1.06)0.13
Calendar time of clinic entry0.77 (0.66 to 0.89)0.0005
Clinical joint damage at first visit (1 unit increase)1.03 (1.01 to 1.05)0.001
NSAID at first visit (yes vs no)1.12 (0.87 to 1.45)0.38
Biological agents at first visit (yes vs no)0.98 (0.59 to 1.62)0.94
DMARD at first visit (yes vs no)1.33 (1.03 to 1.70)0.03
NSAID after first visit (yes vs no)1.44 (0.96 to 2.16)0.08
Biological agents after first visit (yes vs no)1.43 (1.11 to 1.83)0.006
DMARD after first visit (yes vs no)1.62 (1.17 to 2.24)0.003
  • DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.